MSACL 2019 US Abstract

Proteomic Genotyping: When Quantitation Doesn’t Matter, But Quality Still Does

Christopher M. Shuford (1), Meghan N. Bradley (1), Patricia L. Holland (1), Michael Levandoski (1), Russell P. Grant (1)
(1) Laboratory Corporation of America, Burlington, NC

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Christopher Shuford (Presenter) Laboratory Corporation of America

Relevant Financial Disclosures (within past 24 months) Committee/Board/Advisory Board MSACL-US Scientific Committee Stock/Bonds Laboratory Corporation of America Salary Laboratory Corporation of America Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Conflict mitigation IN PROCESS.

Detecting genetic coding variants by bottom-up proteomic methods offers practical advantages over molecular techniques, including the ability to simultaneously quantify variant levels. Indeed, detecting quantifiable levels of a protein variant is a convenient metric for inferring the presence/absence of the corresponding genetic variant; however, in some instances, circulating quantities of the protein variant are not clinically relevant and utilization of a quantitative assay could place undue burden on test implementation or preclude use of non-conventional specimen types such as dried blood or dried plasma less amenable to quantitative measures. To that end, we have developed a targeted, bottom-up protein assay for detecting the presence or absence of Apolipoprotein L1 renal risk variants from liquid and dry plasma specimens based simply on LC-SRM detection with transition ratios.